The UK’s chief scientific adviser has a £600,000 shareholding in a drugs giant contracted to develop a Covid-19 vaccine for the Government, prompting claims of a potential conflict of interest.
- Sir Patrick Vallance, Chief Scientific Adviser to UK Government, was president of GSK 2012 – 2018
- Holds a deferred bonus of 43,111 shares worth £600,000
- Cashed in more than £5m worth of shares upon resignation of GSK
- Sir Vallance special board on vaccines